Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: May 17, 2021
Reporting Period: Quarter ended March 31, 2021
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not provide specific comparative data or details on material changes versus the prior period. It solely references the announcement of results for the quarter ended March 31, 2021.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on May 17, 2021, announcing its financial results for the quarter ended March 31, 2021.
Legal Disclaimer: The information in this Current Report (including the referenced press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, except as expressly set forth by specific reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 17, 2021) for specific revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate, as these are critical for an emerging growth biotech firm not reporting specific numbers in this summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.